Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

41.53
-0.8300-1.96%
Post-market: 41.530.00000.00%19:55 EDT
Volume:1.76M
Turnover:73.64M
Market Cap:10.79B
PE:14.94
High:42.70
Open:42.36
Low:41.49
Close:42.36
52wk High:49.62
52wk Low:32.38
Shares:259.71M
Float Shares:223.00M
Volume Ratio:0.57
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.78
EPS(LYR):2.78
ROE:35.53%
ROA:19.27%
PB:4.99
PE(LYR):14.94

Loading ...

Exelixis Price Target Maintained With a $52.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 03

Earning Preview: Exelixis Q4 revenue is expected to increase by 7.19%, and institutional views are mostly positive

Earnings Agent
·
Feb 03

Exelixis Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
Feb 03

Exelixis reports zanzalintinib new drug application accepted for review by FDA

TIPRANKS
·
Feb 02

FDA Accepts Exelixis Application for Zanzalintinib Combination in Metastatic Colorectal Cancer

Reuters
·
Feb 02

Exelixis Inc - FDA Sets Pdufa Target Action Date for December 3, 2026

THOMSON REUTERS
·
Feb 02

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination With an Immune Checkpoint Inhibitor for Patients With Metastatic Colorectal Cancer

THOMSON REUTERS
·
Feb 02

Morgan Stanley Lifts Price Target on Exelixis to $49 From $48, Keeps Overweight Rating

MT Newswires Live
·
Feb 02

Exelixis Inc. to Release Fourth Quarter and Fiscal Year 2025 Financial Results

Reuters
·
Jan 28

Exelixis Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 27

Exelixis price target raised to $52 from $49 at H.C. Wainwright

TIPRANKS
·
Jan 27

Assessing Exelixis (EXEL) Valuation After Recent Share Price Pullback And Long Term Gains

Simply Wall St.
·
Jan 18

Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating

MT Newswires Live
·
Jan 14

Does Exelixis’ 2026 Revenue Guidance and Zanzalintinib Push Change The Bull Case For EXEL?

Simply Wall St.
·
Jan 14

Exelixis Projects 2026 Net Product Revenues of $2.325 Billion to $2.425 Billion

Reuters
·
Jan 13

Exelixis, Citigroup And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benzinga_recent_news
·
Jan 12

Press Release: Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Dow Jones
·
Jan 12

Barclays Remains a Hold on Exelixis (EXEL)

TIPRANKS
·
Jan 12

Exelixis reports preliminary FY25 revenue $2.32B, consensus $2.33B

TIPRANKS
·
Jan 12

Exelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.62B

TIPRANKS
·
Jan 12